+

PE20060695A1 - Epotilonas en el tratamiento de metastasis osea - Google Patents

Epotilonas en el tratamiento de metastasis osea

Info

Publication number
PE20060695A1
PE20060695A1 PE2005001103A PE2005001103A PE20060695A1 PE 20060695 A1 PE20060695 A1 PE 20060695A1 PE 2005001103 A PE2005001103 A PE 2005001103A PE 2005001103 A PE2005001103 A PE 2005001103A PE 20060695 A1 PE20060695 A1 PE 20060695A1
Authority
PE
Peru
Prior art keywords
alkyl
aryl
aralkyl
epotilones
metastasis
Prior art date
Application number
PE2005001103A
Other languages
English (en)
Inventor
Jens Hoffmann
Ulrich Klar
Hubertus Pietsch
Original Assignee
Schering Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34928830&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20060695(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Ag filed Critical Schering Ag
Publication of PE20060695A1 publication Critical patent/PE20060695A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

SE REFIERE A UNA EPOTILONA DE FORMULA I, DONDE R1a, R1b SON CADA UNO H, ALQUILO C1-C10, ARILO, ARALQUILO, ENTRE OTROS; R2a, R2b SON CADA UNO H, ARILO, ALQUENILO C2-C10, ALQUILO C1-C10, ENTRE OTROS; R3 ES H, ALQUILO C1-C10, ARILO, ARALQUILO; R4a, R4b SON CADA UNO H, ALQUILO C1-C10, ARILO, ARALQUILO, ENTRE OTROS; R5 ES H, ALQUILO C1-C10, ARILO, ARALQUILO, CO2ALQUILO, CH2OH, CN, ENTRE OTROS; R6, R7 SON CADA UNO H, O FORMAN JUNTOS UNA UNION ADICIONAL O FORMAN UNA UNION EPOXI; G ES O, CH2; D-E JUNTOS SON -H2C-CH2-, -HC=CH-, CH(OH)-CH(OH)-, -O-CH2-, ENTRE OTROS; W ES C(=X)R8, AROMATICO, HETEROAROMATICO BI O TRICICLICO; X ES O, O(ALQUILO C1-C20), ENTRE OTROS; R8 ES H, ALQUILO C1-C10, ARILO, ARALQUILO, ENTRE OTROS; Z ES DE PREFERENCIA O, H; A-Y ES O-C(=O), O-CH2, CH2-C(=O), ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (4S,7R,8S,9S,13E/Z,16S)-4,8-DIHIDROXI-16-(2-METIL-BENZOXAZOL-5-IL)-1-OXA-5,5,9,13-TETRAMETIL-7-(PROP-2-EN-1-IL)-CICLOHEXADEC-13-ENO-2,6-DIONA; (1S/R,3S(E),7S,10R,11R,12R,16R/S)-7,11-DIHIDROXI-10-(PROP-2-EN-1-IL)-3-(2-METIL-BENZOXAZOL-5-IL)-8,8,12,16-TETRAMETIL-4,17-DIOXABICICLO[14.1.0]HEPTADECANO-5,9-DIONA; ENTRE OTROS. DICHAS EPOTILONAS SON INHIBIDORES DE LA METASTASIS EN HUESO Y CRECIMIENTO TUMORAL EN HUESOS
PE2005001103A 2004-09-24 2005-09-23 Epotilonas en el tratamiento de metastasis osea PE20060695A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04090377A EP1640004A1 (en) 2004-09-24 2004-09-24 Use of epothilones in the treatment of bone metastases and bone tumors or cancers

Publications (1)

Publication Number Publication Date
PE20060695A1 true PE20060695A1 (es) 2006-08-03

Family

ID=34928830

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001103A PE20060695A1 (es) 2004-09-24 2005-09-23 Epotilonas en el tratamiento de metastasis osea

Country Status (21)

Country Link
EP (2) EP1640004A1 (es)
JP (1) JP2008514569A (es)
KR (1) KR20070054214A (es)
CN (1) CN101065126A (es)
AR (1) AR051035A1 (es)
AU (1) AU2005287477A1 (es)
BR (1) BRPI0516080A (es)
CA (1) CA2580215A1 (es)
CR (1) CR9064A (es)
EC (1) ECSP077390A (es)
GT (1) GT200500267A (es)
IL (1) IL181785A0 (es)
MX (1) MX2007003503A (es)
NO (1) NO20072099L (es)
PA (1) PA8646201A1 (es)
PE (1) PE20060695A1 (es)
RU (1) RU2007115162A (es)
TW (1) TW200626150A (es)
UY (1) UY29136A1 (es)
WO (1) WO2006032537A2 (es)
ZA (1) ZA200703306B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930004A1 (en) * 2006-12-08 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Use of epothilones in the treatment of osteoporosis and related diseases

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
CA2352505C (en) * 1998-12-22 2009-04-07 Novartis Ag Epothilone derivatives and their use as antitumor agents
AR023792A1 (es) * 1999-04-30 2002-09-04 Bayer Schering Pharma Ag Derivados 6-alquenilo- y 6-alquinilo-epotilona, los procedimientos para prepararlos y su empleo en productos farmaceuticos
WO2001024763A2 (en) * 1999-10-01 2001-04-12 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
JP2004508810A (ja) * 2000-04-28 2004-03-25 コーサン　バイオサイエンシーズ，　インコーポレイテッド ポリケチドの生成
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
AU2002338336A1 (en) * 2001-04-03 2002-10-21 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US7211593B2 (en) * 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
DE60328772D1 (de) * 2002-05-01 2009-09-24 Novartis Ag Epothilonderivat zur behandlung von hepatoma und anderen krebserkrankungen
EP1581218A1 (en) * 2002-12-05 2005-10-05 Schering AG Epothilone analogs for site specific delivery in the treatment of proliferative diseases
GB0305928D0 (en) * 2003-03-14 2003-04-23 Novartis Ag Organic compounds
EP1475105A1 (en) * 2003-05-09 2004-11-10 Schering AG Bone localising radiopharmaceutical and tubulin-interacting compound combinatorial radiotherapy
CN1812780A (zh) * 2003-06-27 2006-08-02 诺瓦提斯公司 使用埃坡霉素的癌症治疗
US20060235059A1 (en) * 2003-09-02 2006-10-19 Dilea Clifford Cancer treatment with epothilones

Also Published As

Publication number Publication date
CN101065126A (zh) 2007-10-31
MX2007003503A (es) 2007-08-17
JP2008514569A (ja) 2008-05-08
GT200500267A (es) 2006-06-06
ZA200703306B (en) 2010-06-30
RU2007115162A (ru) 2008-11-20
UY29136A1 (es) 2006-04-28
WO2006032537A3 (en) 2006-05-04
EP1640004A1 (en) 2006-03-29
CA2580215A1 (en) 2006-03-30
IL181785A0 (en) 2007-07-04
NO20072099L (no) 2007-04-23
TW200626150A (en) 2006-08-01
BRPI0516080A (pt) 2008-08-19
AR051035A1 (es) 2006-12-13
KR20070054214A (ko) 2007-05-28
CR9064A (es) 2007-10-01
PA8646201A1 (es) 2006-11-09
ECSP077390A (es) 2007-05-30
AU2005287477A1 (en) 2006-03-30
EP1809281A2 (en) 2007-07-25
WO2006032537A2 (en) 2006-03-30

Similar Documents

Publication Publication Date Title
GT200300059A (es) Compuestos utiles en terapia
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
PE20040747A1 (es) Nuevos conjugados de efectores y procedimientos para su preparacion
LU93078I2 (fr) Combimetinib, éventuellement sous toute forme protégée par le brevet de base, y compris les sels et solvates pharmaceutiquement acceptables, en particulier hémifumarate de cobimetinib
CY1107475T1 (el) Αναστολεις ρο-κινασης
DE602006019221D1 (de) Von dopamin-d3-rezeptoren
AR040971A1 (es) Compuestos pirimido que tienen actividad antiproliferativa
PE20081800A1 (es) NUEVOS DERIVADOS DE 3-([1,2,4]TRIAZOLO[4,3-a]PIRIDIN-7-IL)BENZAMIDA
MY152805A (en) Benzazepine derivatives useful as vasopressin antagonists
AR045595A1 (es) Composiciones utiles como inhibidores de proteinas quinasas
PE20070621A1 (es) 2-amino-7,8-dihidro-6h-pirido(4,3-d)pirimidina-5-onas
PE20050142A1 (es) 2-hidroxi-3-diaminoalcanos de benzamida
CY1111386T1 (el) Ενωσεις και μεθοδοι για αυξηση νευρογενεσης
PE20051061A1 (es) 5,7-DIAMINOPIRAZOLO[4,3-d] PIRIMIDINAS
ECSP045368A (es) "antagonistas de los receptores de trombina"
ATE464049T1 (de) Pharmazeutische kombinationen von hydrocodon und naltrexon
DE60228406D1 (de) PYRAZOLOÄ3,4-dÜPYRIMIDINDERIVATE UND IHRE VERWENDUNG ALS ANTAGONISTEN DES PURINERGEN REZEPTORS
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
CO5580788A2 (es) Compuestos de bencimidazol sustituidos utiles como inhibidores de proteina cinasas
CY1107196T1 (el) Υποκατεστημενα παραγωγα 2,4-διϋδρο-πυρρολο (3,4-β) -κινολιν-9-ονης χρησιμα ως αναστολεις της φωσφοδιεστερασης
PE20061351A1 (es) COMPUESTOS 8H-PIRIDO[2,3-d]PIRIMIDIN-7-ONA 2,4,8-TRISUSTITUIDOS COMO INHIBIDORES DE LA QUINASA CSBP/RK/p38
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
ATE359791T1 (de) Pyrimidin-2,4-dion-derivate als matrix- metalloproteinase-hemmer
PE20091083A1 (es) Moduladores tieno- y furo- pirimidina del receptor de histamina h4

Legal Events

Date Code Title Description
FC Refusal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载